On Thursday, Following U.S. Stocks were among the “Top Losers”: Comtech Telecommunications Corp. (NASDAQ:CMTL), Ply Gem Holdings, Inc (NYSE:PGEM), Molycorp, Inc. (NYSE:MCP), Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX)

Comtech Telecomm. Corp.(NASDAQ:CMTL), with shares declined -15.38%, closed at $26.84.

Ply Gem Holdings Inc(NYSE:PGEM), with shares dropped -15.07%, settled at $11.50.

Molycorp Inc(NYSE:MCP), with shares dipped -15.03%, and closed at $0.65.

Pernix Therapeutics Holdings Inc(NASDAQ:PTX), plummeted -14.72%, and closed at $9.91.

Latest NEWS regarding these Stocks are depicted underneath:

Comtech Telecommunications Corp. (NASDAQ:CMTL)

Comtech Telecommunications Corp. (CMTL), declared that its Board of Directors declared a quarterly cash dividend of $0.30 per share, payable on May 21, 2015, to shareholders of record at the close of business on April 22, 2015. The dividend is the Corporation’s nineteenth successive quarterly dividend. While future dividends will be subject to Board approval, the Board of Directors is presently targeting annual dividend payments aggregating $1.20 per share.

Comtech Telecommunications Corp. designs, develops, produces, and markets products, systems, and services for communications solutions in the United States and internationally. The Corporation believes many of its solutions play a vital role in providing or enhancing communication capabilities when terrestrial communications infrastructure is inaccessible, inefficient or too expensive. The Corporation conducts business through three complementary segments: telecommunications transmission, RF microwave amplifiers and mobile data communications.

Ply Gem Holdings, Inc (NYSE:PGEM)

Ply Gem Holdings, Inc (PGEM), a leading manufacturer of exterior building products in North America, declared financial results for the fourth quarter and year ended December 31, 2014.

Fourth Quarter 2014 Highlights:

• Total net sales for the fourth quarter raised 35.2% to $450.1 million. Not including the favorable influence of the Simonton attainment, our total net sales raised 10.0%.
• Net sales in our Windows and Doors segment raised 61.1% while the Siding, Fencing and Stone segment raised 11.2%. Not including the influence of the Simonton attainment, our net sales in our Windows and Doors segment raised 8.7%.
• Operating earnings raised $11.2 million to $7.9 million contrast to the fourth quarter of 2013.
• Adjusted EBITDA was $26.0 million contrast to $16.0 million for the fourth quarter of 2013.

2014 Year End Highlights:

• Total net sales for 2014 raised 14.7% to $1,566.6 million. Not including the influence of attainments, our net sales raised 4.1%.
• Net sales in our Windows and Doors segment raised 21.9% while the Siding, Fencing and Stone segment raised 8.6%. Not including the influence of attainments, our Windows and Doors’ net sales raised 5.0% while our Siding, Fencing and Stone’s net sales raised 3.3%.
• Operating earnings raised $33.7 million to $61.5 million contrast to 2013.
• Adjusted EBITDA was $124.2 million contrast to $117.5 million for 2013.

Ply Gem Holdings, Inc., together with its auxiliaries, manufactures and sells residential and commercial building products primarily in the United States and Canada.

Molycorp, Inc. (NYSE:MCP)

Molycorp, Inc. (MCP), declared that it will release financial results for the fourth quarter and full year ended December 31, 2014 after the market closes on Monday, March 16, 2015. Release of Molycorp’s financial results will be followed by an investor conference call on Tuesday, March 17, 2015 at 9:00 a.m. Eastern, hosted by Geoff Bedford, President and Chief Executive Officer, and Michael Doolan, Executive Vice President and Chief Financial Officer.

Molycorp is the only advanced material manufacturer in the world that both controls a world-class rare earth resource and can produce high-purity, custom engineered rare earth products to meet increasingly demanding customer specifications.

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX)

Pernix Ireland Limited, a wholly owned partner ofPernix Therapeutics Holdings, Inc. (PTX), a specialty pharmaceutical corporation, declared that it has signed a definitive contract to attain the Zohydro ER franchise from Zogenix, Inc. (ZGNX). The attainment comprises three extended release hydrocodone products, counting an abuse-deterrent pipeline and all related intellectual property. Pernix has agreed to pay $100 million at closing, plus regulatory and commercial milestones of up to $283.5 million if the Zohydro ER franchise achieves agreed-upon net sales targets of up to $1 billion annually.

Planned Rationale:

• Represents 100% expansion of the Pernix Specialty Sales Organization, creating a platform for rapid growth and future attainments
• Unique product franchise at early stages of launch, with an attractive competitive environment
• Excellent planned fit with the Corporation’s CNS focus — provides immediate sales synergies in a formerly untapped market segment for Silenor®
• Establishes a platform for Pernix to become a leading player in the opioid pain market
• Transaction is predictable to provide immediate top-line contribution, and meaningful EBITDA contribution in 2016
• IP runway anticipated up to 2030 providing long-term growth trajectory for Pernix.

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical corporation, develops, manufactures, markets, and sells branded and generic pharmaceutical products.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.